<DOC>
	<DOCNO>NCT01951222</DOCNO>
	<brief_summary>Recent large clinical study demonstrate interest LAMA therapy management asthma , compare LABA . V0162 compound long lasting bronchodilator effect compare reference treatment non-clinical model COPD patient . Secondary property V0162 ( i.e.H1/H4 PDE IV-inhibition ) could enhance efficacy antimuscarinic compound could bring option treatment obstructive lung disease . The objective study ass bronchodilator property V0162 8 day adult patient asthma usually treat ICS LABA . The study randomise , double-blind , placebo-controlled , 3-period crossover , precede open-label active-control period randomisation .</brief_summary>
	<brief_title>Bronchodilator Properties Safety Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<criteria>Aged 18 65 yearsold . 18 ≤ BMI &lt; 30 kg/m² . Clinical history consistent asthma , judgement investigator . Asthma control partly control accord GINA 2012 criterion : Asthma treat ICS LABA ( fixeddose combination free combination ) stable dose least 3 month . Able replace usual ICS LABA therapy ICS usual dose regimen salbutamol need . Able stop salbutamol least 6 hour study visit . Able perform least 3 acceptable reproducible FEV1 FVC measurement accord ERS/ATS 2005 recommendation . Clinically significant respiratory condition asthma ( e.g . pneumonia , pneumothorax , atelectasis , bronchiectasis , chronic bronchitis , COPD , emphysema , pulmonary arterial hypertension , pulmonary fibrosis , etc. ) . Upper low respiratory tract infection within 4 week . Exacerbation ( require oral corticosteroid hospitalization ) within 3 month . Current smoker former smoker le 6 month total lifetime smoke history great 10 packyears . Intolerance salbutamol . Intolerance tiotropium ( atropinederived compound ) . Intolerance one ingredient study product Severe hepatic impairment , moderate severe renal impairment , epilepsy , narrow angle glaucoma , gastrointestinal obstruction , moderate severe prostatic hypertrophy , bladder neck obstruction . Any acute chronic disease allow participation study , judgement investigator . Clinically relevant physical examination abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Asthma , COPD , broncodilator , airway , lung , inhalation , antimuscarinic</keyword>
</DOC>